Inloggad som:

MOMENTUM SRA-MMB 301

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

MOMENTUM SRA-MMB 301
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Ej tillämpbar
Företag

Studien ändrades senast av: Caroline Brav (2020-12-02)

Tillbaka till listan